Corona Remedies
Corona Remedies (CORONA) share price was ₹2,200.60 at the 28 Oct 2026 close; market capitalisation ₹13,459 Cr; P/E (TTM) 67.77; sector Healthcare. In the Jun 2026 quarter, revenue rose 21.9% year on year to ₹422.4 Cr and net profit rose 30.1% year on year to ₹60.1 Cr (compared with Jun 2025). Promoters held 69.00% of Corona Remedies in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 56/100 (Good) as of 28 Oct 2026.
Key Fundamentals
MicrocapPharmaceuticalsHealthcarePrice-based figures as of 28 Oct 2026, 15:31 IST · EPS basis: Standalone · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,757.50 | 34.86 | 4,21,683 Cr | 5.05 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,558.50 | 86.75 | 2,53,748 Cr | 15.14 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,557.00 | 71.54 | 1,73,334 Cr | 9.43 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,181.90 | 107.80 | 1,17,891 Cr | 22.24 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,175.50 | 26.16 | 1,17,257 Cr | 4.33 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,335.40 | 34.59 | 1,11,463 Cr | 2.87 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,365.60 | 32.72 | 1,10,321 Cr | 3.12 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Corona Remedies (this company) | ₹2,200.60 | 67.77 | 13,459 Cr | 18.02 | 0.46% | 24.79% | 29.31% | 1,491 Cr | 198 Cr |
| Median 8 companies | ₹1,969.70 | 51.32 | 1,17,574 Cr | 7.24 | 0.54% | 14.56% | 18.45% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
v2.0.0
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company has delivered good profit growth of 23.3% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%
- Company has been maintaining a healthy dividend payout of 29.4%
Weaknesses
2- Stock is trading at 16.8 times its book value
- Company might be capitalizing the interest cost
Technical Indicators
Oscillators
Neutral
Overall
Bullish
Moving Averages
Bullish
2 of 2 analysts rate Buy, 0 Hold, 0 Sell.
Updated 28 Oct 2026
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 22% · Jun 2026
AI Analysis — Bull vs Bear
Corona Remedies Ltd trades at ₹2,200.6 as of 2026-10-28 with a market cap of ₹13,458.89 Cr, a trailing PE of 67.77x, and ROE of 24.79%. The company has demonstrated strong compounded profit growth of 23% CAGR over five years alongside low leverage at 0.22x debt-to-equity, but its valuation at 18.02x book value and nearly 68x trailing earnings places it at a significant premium to broader market averages.
- Strong profit growth trajectory with compounded profit CAGR of 23% over 5 years and an accelerating 33% CAGR over the last 3 years, indicating improving earnings momentum
- High return on equity of 24.79% (TTM) backed by a consistent 3-year average ROE of 26% and last year's ROE of 30%, reflecting efficient capital allocation
- Robust return on capital employed of 29.31%, well above typical cost of capital, suggesting the business generates genuine economic value
- Conservative balance sheet with debt-to-equity of just 0.22x, providing financial flexibility and resilience during industry downturns
- Healthy compounded sales growth of 19% CAGR over 5 years with TTM sales growth at 18%, indicating sustained top-line expansion without significant deceleration
- Consistent dividend payout ratio of 29.4% demonstrates shareholder-friendly capital return policy, with a current dividend yield of 0.46%
- TTM profit growth of 28% is outpacing TTM sales growth of 18%, suggesting margin expansion and operating leverage in the business model
- Stock is trading at ₹2,200.6, which is 64.6% above its 52-week low of ₹1,336.6, reflecting sustained investor interest and positive price momentum over the past year
- Trailing PE of 67.77x is significantly elevated compared to broader Indian market averages of 20-25x, leaving limited margin of safety if growth slows
- Price-to-book ratio of 18.02x is extremely high, meaning investors are paying a steep premium over the company's net asset value
- Potential capitalisation of interest costs, as flagged in known concerns, could mean reported profits overstate true operating profitability and inflate ROE figures
- EPS of ₹32.47 (TTM) implies that even modest earnings disappointment could trigger a sharp de-rating given the 67.77x PE multiple
- Dividend yield of only 0.46% offers minimal income cushion, meaning investor returns are almost entirely dependent on continued price appreciation
- Stock is trading just 4% below its 52-week high of ₹2,292.4, which at current valuations leaves it vulnerable to mean-reversion if sector sentiment shifts
- At a market cap of ₹13,458.89 Cr with a small-to-mid-cap profile in the Indian healthcare space, the stock may face liquidity constraints during broad market sell-offs
- Ten-year growth data is unavailable for sales, profit, and ROE, limiting visibility into longer-term cyclicality and the sustainability of recent high-growth trends
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- ANVISA GMP for Brazil exports Oct 22
Secured ANVISA GMP certification for OSD and hormone facilities in Ahmedabad, opening access to Brazil's $44 billion pharma market. This is the company's third major international GMP accreditation, adding to existing EU and EAEU approvals.
- India dominates revenue mix Oct 22
Despite the new Brazilian certification, India remains the primary market contributing over 96% of total revenue, meaning near-term financial impact from exports may be limited.
TL;DR: Corona Remedies is steadily building international regulatory credentials with its third major GMP accreditation (ANVISA), following EU and EAEU approvals. The $44B Brazilian market represents a meaningful long-term export opportunity. However, with India still accounting for over 96% of revenue, international diversification remains early-stage. The trend is cautiously positive as the company lays groundwork for future export-driven growth.
Analyst Forecasts
Quarterly Results
| Particulars | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 314 | 298 | 294 | 347 | 361 | 342 | 353 | 422 |
| Expenses | 247 | 228 | 239 | 277 | 283 | 259 | 291 | 329 |
| Operating Profit | 67 | 69 | 54 | 70 | 78 | 83 | 62 | 93 |
| OPM % | 21% | 23% | 18% | 20% | 22% | 24% | 18% | 22% |
| Other Income | 2 | 1 | 1 | 2 | 2 | -17 | 4 | 3 |
| Interest | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 3 |
| Depreciation | 9 | 10 | 10 | 9 | 9 | 9 | 10 | 13 |
| PBT | 57 | 58 | 43 | 61 | 70 | 55 | 54 | 80 |
| Tax % | 25% | 23% | 28% | 24% | 25% | 25% | 17% | 25% |
| Net Profit | 43 | 45 | 31 | 46 | 52 | 41 | 45 | 60 |
| EPS (₹) | 7.03 | 7.32 | 5.12 | 7.59 | 8.53 | 6.74 | 7.37 | 9.83 |
Profit & Loss
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 509 | 601 | 576 | 617 | 884 | 1,014 | 1,196 | 1,403 | 1,479 |
| Expenses | 444 | 509 | 471 | 600 | 756 | 859 | 956 | 1,109 | 1,162 |
| Operating Profit | 66 | 93 | 105 | 18 | 128 | 156 | 241 | 294 | 317 |
| OPM % | 13% | 15% | 18% | 2.9% | 14% | 15% | 20% | 21% | 21% |
| Other Income | 3 | 3 | 5 | 7 | 7 | 5 | 5 | -9 | -7 |
| Interest | 1 | 2 | 2 | 5 | 4 | 14 | 11 | 7 | 8 |
| Depreciation | 14 | 16 | 16 | 20 | 20 | 28 | 37 | 38 | 42 |
| PBT | 54 | 77 | 92 | -1 | 111 | 118 | 198 | 240 | 260 |
| Tax % | 35% | 24% | 24% | -49% | 23% | 24% | 25% | 23% | — |
| Net Profit | 35 | 59 | 70 | 0 | 85 | 90 | 149 | 185 | 199 |
| EPS (₹) | 6.8 | 11.51 | 13.69 | -0.08 | 13.85 | 14.8 | 24.37 | 30.22 | 32.47 |
| Div. Payout % | 0% | 0% | 0% | 0% | 20% | 25% | 30% | 33% | — |
Balance Sheet
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 51 | 61 | 61 | 61 | 61 |
| Reserves | 204 | 263 | 333 | 270 | 347 | 419 | 545 | 685 |
| Borrowings | 13 | 47 | 50 | 34 | 28 | 159 | 86 | 165 |
| Other Liabilities | 71 | 94 | 144 | 157 | 159 | 191 | 237 | 293 |
| Total Liabilities | 293 | 408 | 532 | 511 | 595 | 830 | 929 | 1,204 |
| Fixed Assets | 80 | 81 | 164 | 162 | 185 | 384 | 370 | 554 |
| CWIP | 4 | 42 | 0 | 14 | 65 | 121 | 186 | 143 |
| Investments | 9 | 7 | 37 | 14 | 31 | 25 | 25 | 25 |
| Other Assets | 200 | 278 | 330 | 321 | 314 | 301 | 348 | 482 |
| Total Assets | 293 | 408 | 532 | 511 | 595 | 830 | 929 | 1,204 |
Cash Flow
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | 19 | 43 | 79 | 98 | 103 | 157 | 190 | 229 |
| Investing | -23 | -50 | -102 | -66 | -50 | -267 | -84 | -256 |
| Financing | 4 | 30 | 0 | -30 | -45 | 99 | -107 | 25 |
| Net Cash Flow | -1 | 23 | -23 | 2 | 8 | -11 | 0 | -1 |
| Free Cash Flow | 19 | 1 | 6 | 64 | 9 | -129 | 99 | 56 |
| CFO/EBITDA | 49 | 65 | 101 | 557 | 100 | 112 | 97 | 95 |
Ratios
| Particulars | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 95 | 105 | 131 | 44 | 36 | 36 | 36 | 38 |
| Inventory Days | 69 | 52 | 77 | 184 | 182 | 158 | 200 | 175 |
| Days Payable | 126 | 110 | 182 | 211 | 163 | 184 | 221 | 206 |
| Cash Conversion Cycle | 38 | 48 | 27 | 17 | 55 | 10 | 14 | 7 |
| Working Capital Days | 67 | 81 | 86 | 16 | 30 | -2 | 9 | -15 |
| ROCE % | — | 30% | 27% | 1% | 29% | 25% | 31% | 33% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Corona Remedies insights
70 extracted metrics + investor summaries across FY19–FY27.
Documents
Frequently Asked Questions about Corona Remedies
What does Corona Remedies Ltd do?
Where is Corona Remedies Ltd (CORONA) listed?
Which sector does Corona Remedies Ltd belong to?
What is the market capitalisation of Corona Remedies Ltd?
What is the PE ratio of Corona Remedies Ltd?
What is the 52-week high and low of Corona Remedies Ltd?
Does Corona Remedies Ltd pay dividends?
What is the Return on Equity (ROE) of Corona Remedies Ltd?
Company Information
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CORONA.md for Corona Remedies Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.